microPublication

Get Your Data Out, Be Cited

  • About
    • Editorial Policies
      • Editorial Staff
      • Editorial Board
      • Criteria For Publication
      • Publishing Information
      • Data Sharing Policy
    • For Authors
      • Preparation And Submission Of A Manuscript
      • Peer Review Process
      • Following Acceptance
      • Appeals
    • For Reviewers
    • Why micropublish?
  • Submit a microPublication
  • Journals
    • microPublication Biology
      • Editorial Board
  • microPublications
    • Biology
      • Species
        • Arabidopsis
        • C. elegans
        • D. discoideum
        • Drosophila
        • Human
        • Mouse
        • S. cerevisiae
        • S. pombe
        • Xenopus
        • Zebrafish
      • Categories
        • Phenotype Data
        • Methods
        • Expression Data
        • Genotype Data
        • Integrations
        • Genetic Screens
        • Models of Human Disease
        • Software
        • Interaction data
        • Database Updates
        • Electrophysiology Data
        • Phylogenetic Data
        • Science and Society
        • Biochemistry
  • Contact
  • More
    • Archives
    • FAQs
    • Newsletter
microPublication / Biology / ARENA-based activity profiling of tau...
ARENA-based activity profiling of tau and TDP-43 transgenic C. elegans
Heather N Currey1, Anna Malinkevich2, Penny Melquist2 and Nicole F Liachko1,3
1Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108 USA
2InVivo Biosystems (formerly NemaMetrix, Inc.), Eugene, OR 97402, USA
3Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington, Seattle, WA 98104, USA
Correspondence to: Nicole F Liachko (nliachko@uw.edu)
Figure 1. Activity differences of day 1 adult neurodegenerative disease model C. elegans measured by changes in LED microbeam disruption: (A) Expression of mutant (tau V337M, strain CK10) or wild-type (tau WT, strain CK144) human tau pan-neuronally causes significant activity differences compared to N2. tau V337M and tau WT are also significantly different from each other. Graph displays aggregate population activity per minute. ***p=0.0005, ****p<0.0001, one-way ANOVA with Tukey’s multiple comparison’s test. Data from 3 independent replicate experiments, N=30 worms per replicate. (B) Expression of wild-type (TDP-43 WT, strain CK410) or mutant (TDP-43 M337V, strain CK423 and TDP-43 A315T, strain CK426) human TDP-43 pan-neuronally causes significant activity differences compared to N2. Each TDP-43 strain was also significantly different from each other. Graph displays aggregate population activity per minute. *p=0.02, ****p<0.0001, one-way ANOVA with Tukey’s multiple comparison’s test. Data from 4 independent replicate experiments, N=30 worms per replicate.

Description

Aggregates of the protein tau are the hallmark of several neurodegenerative diseases including Alzheimer’s disease, frontotemporal lobar degeneration (FTLD-tau), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick’s disease, and chronic traumatic encephalopathy (CTE) (VandeVrede, Boxer et al. 2020). Mutations in the gene coding for tau, MAPT, can cause FTLD-tau, directly linking tau dysfunction with disease (Dickson, Kouri et al. 2011). Another protein, TDP-43, comprises aggregates which are the primary hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP), and mutations in the gene coding for TDP-43, TARDBP, can cause disease (Kawakami, Arai et al. 2019). To model tau or TDP-43 proteinopathies, transgenic C. elegans have been generated that express the full-length human protein pan-neuronally. These worms exhibit significant uncoordinated movement on plates and impaired thrashing in liquid (Kraemer, Zhang et al. 2003; Liachko, Guthrie et al. 2010). However, tau- and TDP-43- expressing worms are not paralyzed; they still move their heads and have some motility on the plate (coiling, crawling with tail-drag, head swinging) which are not captured in standard crawling or thrashing assays. To assay differences in total activity, we used a WMicroTracker ARENA System (Phylumtech, AR and InVivo Biosystems, USA). The ARENA captures population level activity data by relying on optical interferometry, which uses a large array of infrared LED microbeams to detect both the movement and position of worms on a culture plate. Disruption of an LED microbeam by worm movement is recorded by repeat scans of the 6-well culture plate, and allows for real-time processing. The software identifies changes in the location of disrupted beams between scans and assigns an activity score based on differences identified between each consecutive scan (Simonetta SH). Both tau- and TDP-43- expressing worms had significantly less activity per minute than N2 (Figure 1). Further, we found the ARENA- assessed activity data recapitulated the relative severity of phenotypes among the strains as measured by motility assays. For example, both CK10 (tau V337M) and CK144 (tau WT) have significantly uncoordinated movement when crawling or thrashing in liquid, with CK144 having worse motility than CK10, due to its much higher burden of total tau protein expressed (Kraemer, Zhang et al. 2003). Likewise, CK410 (TDP-43 WT) worms have slightly impaired motility compared with N2 when crawling on a plate, CK423 (TDP-43 M337V) are severely uncoordinated, and CK426 (TDP-43 A315T) have the most severe uncoordinated phenotype. The relative toxicities of these strains stem from the effects of the mutations, as TDP-43 protein expression is relatively even among these transgenic strains (Liachko, Guthrie et al. 2010). Interestingly, the ARENA captures activity of these severely uncoordinated worms that move poorly in motility assays such as crawling on an NGM plate or thrashing in liquid (Kraemer, Zhang et al. 2003; Liachko, Guthrie et al. 2010). Therefore, ARENA assessment of aggregate activity may be a more accurate metric for capturing non-locomotor movement of C. elegans that are severely uncoordinated.

Methods

Request a detailed protocol

ARENA Tracking

All worms used were staged by way of timed egglay, and grown at 16oC on NGM plates seeded with OP50 E. coli to day 1 adult. The experiment was performed in a 6-well plate prepared with 3.5mL NGM per well and seeded with OP50. The worms were picked from stock plates into a prepared 6-well plate, 30 worms per strain, each strain in a unique well. Recordings were performed at room temperature (approximately 22oC). The plate was placed in the ARENA 15 minutes before starting the run to allow worms to acclimate. 14 activity scores were collected per strain over 60 minutes. Statistical analysis was performed with GraphPad Prism 8.

Reagents

Strains Used

N2 Bristol

CK10 bkIs10 [aex-3p::tau(V337M 4R1N); myo-2p::dsRED] III

CK144 bkIs144 [aex-3p::tau(WT 4R1N); myo-2p::dsRED] IV

CK410 bkIs410 [snb-1p::TDP-43(WT); myo-2p::dsRED] II

CK423 bkIs423 [snb-1p::TDP-43(M337V); myo-2p::dsRED] IV

CK426 bkIs426 [snb-1p::TDP-43(A315T); myo-2p::dsRED] II

Acknowledgments

We thank Dr. Brian Kraemer for strains and expert advice. We thank the Department of Veterans Affairs for funding.

References

Dickson, D. W., N. Kouri, M. E. Murray and K. A. Josephs (2011). Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci 45(3): 384-389.
PubMed
Kawakami, I., T. Arai and M. Hasegawa (2019). The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol 138(5): 751-770.
PubMed
Kraemer, B. C., B. Zhang, J. B. Leverenz, J. H. Thomas, J. Q. Trojanowski and G. D. Schellenberg (2003). Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A 100(17): 9980-9985.
PubMed
Liachko, N. F., C. R. Guthrie and B. C. Kraemer (2010). Phosphorylation Promotes Neurotoxicity in a Caenorhabditis elegans Model of TDP-43 Proteinopathy. J Neurosci 30(48): 16208-16219.
PubMed
Simonetta SH, Santa Cruz MJ, Phylumtech SA. Procedure and automatic recording device for locomotion of nematodes or small organisms of similar sizes by temporary interferometry of light microbeams. Patent number AR20190100121 and PCT/ES2020/070029.
VandeVrede, L., A. L. Boxer and M. Polydoro (2020). Targeting tau: Clinical trials and novel therapeutic approaches. Neurosci Lett 731: 134919.
PubMed

Funding

Department of Veterans Affairs Merit Review Grant #I01BX004044 to N.L.

Author Contributions

Heather N Currey: Conceptualization, Formal analysis, Investigation, Methodology, Validation, Writing - original draft, Writing - review and editing, Visualization
Anna Malinkevich: Conceptualization, Methodology, Writing - review and editing
Penny Melquist: Conceptualization, Methodology, Writing - review and editing
Nicole F Liachko: Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Visualization, Writing - original draft, Writing - review and editing, Conceptualization.

Reviewed By

Alex Parker

History

Received: June 22, 2020
Revision received: July 13, 2020
Accepted: July 16, 2020
Published: July 16, 2020

Copyright

© 2020 by the authors. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation

Currey, HN; Malinkevich, A; Melquist, P; Liachko, NF (2020). ARENA-based activity profiling of tau and TDP-43 transgenic C. elegans. microPublication Biology. 10.17912/micropub.biology.000278.
Download: RIS BibTeX
microPublication Biology is published by
1200 E. California Blvd. MC 1-43 Pasadena, CA 91125
The microPublication project is supported by
The National Institute of Health -- Grant #: 1U01LM012672-01
microPublication Biology:ISSN: 2578-9430